Reportlinker Adds Global Cardiovascular Disease Diagnostics Industry
NEW YORK, March 21, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Cardiovascular Disease Diagnostics Industry
http://www.reportlinker.com/p087285/Global-Cardiovascular-Disease-Diagnostics-Industry.html
This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following product segments - Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 71 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Biosite, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biomerieux, Cambridge Heart, Inc., Cholestech Corp., GE HealthCare, Home Access Health Corporation, LifeSign LLC, Liposcience, Inc., Nanosphere, Inc., Ortho-Clinical Diagnostics, Inc., Philips Healthcare, Polymer Technology Systems, Inc., Response Biomedical Corp., Roche Diagnostics, Siemens Healthcare Diagnostics, Inc., St. Jude Medical, Inc., and EP MedSystems. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
In Vitro Diagnostics 3
In Vivo Diagnostics 3
2. INDUSTRY OVERVIEW 5
Cardiovascular Diseases: The Undying Challenge 5
Table 1: Region-Wise Incidence and Prevalence of
Cardiovascular Diseases in 2006 6
Mounting Healthcare Costs - Calls for Early Diagnosis 6
Cardiovascular Disease Diagnostics: Playing a Pivotal Role in
Early Disease Detection 6
Developed Countries Dominate, Developing to be the Future
Growth Engine 7
Fast and Accurate Diagnosis - Reduce Unnecessary Healthcare Costs 7
POC Diagnostics Market Gains Momentum 8
Cardiac Markers - Making Diagnosis Easier and Quicker 8
Major Cardiac Markers and their Properties 9
What's New in POC Cardiac Markers Space? 9
Leading Players 10
List of Point of Care Cardiac Marker Testing Products 10
3. IN-VIVO DIAGNOSTICS 11
Table 2: Global In-vivo Cardiovascular Disease Diagnostics
Market by Region: 2010 (includes corresponding Graph/Chart) 11
Novel Imaging Techniques Boost In vivo Diagnostics Market 11
Non-Invasive Procedure Hogs the Limelight for Cardiovascular
Treatment 12
Cardiology Diagnostic Imaging 12
New Technologies Bring Diagnostics Closer to Patients 12
Trends Cited in the Imaging Technologies Market 13
CT Scanners 13
MRI 14
Move Towards Efficient Patient Data Management 14
4. IN-VITRO DIAGNOSTICS 15
A Quick Insight into the Global In-vitro Diagnostics Market 15
Growth Trends 15
Developed Countries Drive In-Vitro Diagnostics (IVD) Market 15
Table 3: Leading In-Vitro Diagnostics Markets Worldwide
(2007): Percentage Breakdown for North America, Europe,
Japan, and Others (includes corresponding Graph/Chart) 16
Established Players Dominate the Fragmented Market 16
Table 4: Leading Players in the Global In-Vitro Diagnostics
Market (2009): Percentage Breakdown of Value Sales for Roche
Diagnostics, Abbott Diagnostics, Ortho/ LifeScan,
Bayer/Siemens, Beckman Coulter, BD, Dade Behring, bioMerieux
and Others (includes corresponding Graph/Chart) 16
Point-of-Care In-Vitro Testing on the Roll 17
Table 5: Global In vitro Diagnostics Market by Type of Test
(2007): Percentage Breakdown for Central Lab Testing,
Point-of-Care Testing, and Molecular Testing (includes
corresponding Graph/Chart) 17
A Specific Focus on Global Cardiovascular In-Vitro Diagnostics
Market 17
Market Analysis 18
Table 6: World Cardiovascular In-vitro Diagnostics Market:
2010 (includes corresponding Graph/Chart) 18
Aging Population Drives Home Testing Market 18
Cholesterol and Other Cardiovascular Test Kits Offered by
Leading Companies 19
Development of Home Cholesterol Testing Kits 19
Table 7: Global Cholesterol Point-of-Care Rapid Tests Market
(2009): Market Shares of Leading Players by Value Sales for
Inverness Medical, Roche, Abaxis, and Others (includes
corresponding Graph/Chart) 19
Strong Demand for Risk Assessment Markers 19
Advancements in Alternate-Site Coagulation Monitoring 20
5. CVD - CAUSE AND RISK FACTORS 21
CVD - Global Facts 21
Table 8: CVD Death Rates (per 100,000 population) Among Men
(Aged 35-74 years) by Select Country: 2007 (includes
corresponding Graph/Chart) 21
Table 9: CVD Death Rates (per 100,000 population) Among Women
(Aged 35-74 years) by Select Country: 2007 (includes
corresponding Graph/Chart) 22
Atherosclerosis - Leading Cause for CVD 22
Risk Factors 22
Irreversible Risk Factors 22
Increasing age 22
Sex (gender) 23
Heredity (including Race) 23
Risk Factors that can be controlled 23
Tobacco Smoke 23
High Blood Cholesterol 23
LDL Cholesterol 24
HDL Cholesterol 24
Triglyceride levels 24
Hypercholesterolemia - Conditions Associated with
Cholesterol Level 25
High Blood Pressure 25
BP - Leading Cause of Cardiovascular Disease in Young Adults 26
Physical Inactivity 26
Obesity and Overweight 26
Diabetes Mellitus 26
Cardiovascular Disease and Homocysteine Levels 26
Measures for Reducing Cardiovascular Diseases 27
6. CARDIOVASCULAR DISEASE AND CONDITIONS 28
Angina Pectoris 28
Arrhythmias 28
Sudden Cardiac Death (SCD) 28
Stroke 28
Congestive Heart Failure 29
Heart Failure Classification as per the NYHA and ACC/AHA 29
Table 10: Prevalence Rates of Congestive Heart Failure in
Select Countries (per 10,000) (includes corresponding
Graph/Chart) 30
Cardiovascular Disease Involving Transplant Patients 30
7. DIAGNOSTIC TESTS FOR CARDIOVASCULAR DISEASES 31
In-Vitro Cardiovascular Diagnostics 31
Cholesterol Testing 31
Use of Markers 31
Creatine Kinase MB 31
Troponin T and Troponin I 32
C-Reactive Protein 32
Plasminogen Activator Inhibitor-1 33
D-Dimer 33
Thrombus Precursor Protein 33
Other Cardiac Markers 33
Increasing Popularity of Risk Assessment Markers 33
A Step Forward in Cardiovascular Risk Assessment 34
In Vivo Diagnostic Tests 34
Computed Imaging / Tomography 34
Electron Beam Computed Tomography (EBCT) 34
Appropriate Conditions for EBCT Diagnosis 35
Cardiac Positron Emission Tomography (PET) 35
Digital Cardiac Angiography/ Digital Subtraction Angiography 36
Magnetic Resonance Imaging (MRI) 36
Single Photon Emission Computed Tomography (SPECT) 37
Echocardiography 37
Different Types of Echo-techniques 37
M-mode (Motion mode, One-dimensional) 37
Two-Dimensional (Cross-sectional) 38
Stress Echocardiogram (Stress Echo) 38
Transesophageal Echocardiogram (TEE) 38
Risks 38
Ultrasound Tests 38
Doppler Ultrasound 38
Intravascular Ultrasound 39
Working 39
Comparative Facts Related to Definitive Diagnosis of
Cardiovascular Disease 39
Nuclear Cardiology Tests 40
Applications 40
Types of Nuclear Cardiology Tests 40
Myocardial Perfusion Imaging 40
Applications 41
Risks 41
Ventricular Function Test 41
Testing Cardiac Stress 42
Cardio Vascular Disease Diagnostics Tests in the Pipeline 42
Aderis MRE-0470 42
CardioMEMS Novel Technology 42
Technology Platform 42
8. PRODUCT LAUNCHES AND DEVELOPMENTS 43
Cardiac Science Launches Microvolt T-Wave Alternans Module 43
Cleveland HeartLab to Extend Test Menu 43
St. Jude Medical Introduces EnSite Derexi Module 43
NorDiag Unveils NorDiags Arrow Instrument 44
Biosense Webster Launches CARTO® 3 System 44
McKesson Unveils New Variant of Horizon Cardiology
Cardiovascular Information System 44
Correlagen Launches CardioGeneScan Test 44
Royal Philips Electronics to Launch PageWriter TC50 Cardiograph 45
Philips Introduces Xcelera R3.1 45
St. Jude Medical Launches Medical Devices for Heart Rhythms
Disorders 45
TomTec and Medis Launches Cardiac Imaging and Analysis Product 46
Royal Philips Electronics Launches PageWriter TC70 46
Philips Healthcare to Introduce CX50 CompactXtreme 47
Royal Philips Electronics Introduces Xcelera R2.2 47
Toshiba America to Launch AplioTM Artida 47
9. PRODUCT LAUNCHES AND DEVELOPMENTS IN THE RECENT PAST - A
PERSPECTIVE BUILDER 49
Philips Rolls Out 256-slice CT scanner, Brilliance iCT Scanner 49
Royal Philips Launches Live 3D Transesophageal Echocardiogram
Probe 49
GE Healthcare Launches Vivid e Ultrasound Systems 49
Cardionetics Launches ECG Monitor for 24-Hour Real-Time
Cardiac Diagnosis 49
Siemens Launches Imaging Release for the ACUSON Sequoia Platform 50
GE Healthcare Launches Version 2.0 of Centricity Cardiology
CA1000 50
GE Healthcare Introduces New Capabilities to CardioSoft
Diagnostic Software 50
GE Healthcare's Lightspeed VCT Offers Imaging at 70% Lower
Exposure 50
Roche Diagnostics Launches cobas h 232 Portable Cardiac Marker
System (Outside US) 51
Royal Philips Launches New Imaging Tool for Complex Cardiac
Arrhythmias 51
Siemens Medical Introduces syngo® US, New Echocardiography
Solution. 51
Dade Behring Introduces CardioPhase® hsCRP Test for Multiple
Testing Platforms. 51
Shimadzu Launches Two Models in Angiographic Imaging 52
Omron Healthcare Introduces Non Invasive Vascular Profiling
System 52
Abbott Launches XIENCE V, New Coronary Stent System 52
Siemens Medical Introduces Acuson AcuNav 8F, an Advanced
Ultrasound Catheter 52
BioMerieux Introduces High Performance VIDAS Troponin I Ultra 53
Siemens Launches Acuson X300 Ultrasound Platform 53
Siemens Releases Web-Enabled CT 53
GE Introduces Latest Electrocardiograph Device, MAC 3500 54
GE Emphasizes on the Striking Features of New Vivid 7
Dimension '06 54
GE Launches Latest Innova Digital Flat Panel Biplane Imaging
Devices 54
Medtronic Introduces Latest Range of Implantable Cardiac
Defibrillators 55
Philips Introduces Web Based Cardiac Tools 55
Siemens Showcases Solutions for Cardiac Problems Through
Molecular Imaging 55
Siemens Presents Advancements in Echocardiography 55
Siemens Debuts syngo BEAT 56
Siemens Combines syngo® Dynamics with Soarian® for
Cardiovascular EPR 56
GE Healthcare Unveils CardIQ Fusion 56
GE Introduces Discovery VCT 56
GE Unveils Dynamic VUE 56
GE Launches CardIQ Xpress 57
GE Presents the Ventri for Cardiac Imaging 57
GE Introduces High Definition Magnetic Resonance System 57
Dade Behring Unveils CardioPhase(R) hsCRP Test 57
Siemens Launches Encompass III on C512 Ultrasound Platform 57
Siemens Launches Four New CT Clinical Engines 58
Omron Launches HEM-9000AI Cardiovascular Diagnostic Tool 58
Corgenix Introduces Predictive Cardiovascular Diagnostic Kit,
AtherOx™ 58
Philips Introduces HD11 XE Cardiology Ultrasound System 58
Siemens Introduces Biplane FD Cardiology System 59
Siemens Introduces Syngo Circulation Software for CT Tomography 59
Siemens Introduces SOMATOM Definition for Cardiac Imaging 59
Dade Behring Unveils Homocysteine Test on BN (TM) Systems 59
Roche Unveils Cardiac pro-BNP Test 59
Philips Introduces HD11 XE 60
Corgenix Unveils AtherOx(TM) 60
GE Healthcare Unveils Breakthrough Imaging Technology 60
Philips Launches Products to Detect Heart Problems 60
Philips Unveils Computed Tomography and EP Planning package 61
Philips Widens Magnetic Resonance Portfolio 61
New Cardiac Monitoring Products from Philips 61
Siemens Launches Image-Arena 61
Siemens Announces New Procam-Calculator Combined with CT
Examination 61
Siemens Medical Solutions Launches Axiom Artis dTA 62
GE Healthcare Unveils Vivid i 62
GE Healthcare Presents Fully Integrated 4D Cardiovascular
Ultrasound System 63
GE Healthcare Debuts New Imaging System 63
New Discovery PET/CT Systems from GE Healthcare 63
SonoSite Presents SonoCalc IMT Software 63
Dade Behring Introduces High Sensitivity Troponin I Assay 64
Biosite Unveils New Diagnostic Test 64
MDS Diagnostic Services Unveils New Test to Prevent Heart Disease 64
diaDexus Develops PLAC Test 65
Siemens Introduces New Nuclear Cardiology Imaging System 65
Roche Diagnostics Receives U.S. Clearance and European CE Mark 65
Camtronics Unveils Cardiovascular Screening Software 66
Mayo Pioneers New Enzyme-Based Cardiovascular Risk Assessment
Test 66
10. RECENT INDUSTRY ACTIVITY 67
Inverness Changes Name to Alere 67
Miraculins Acquires PreMD's PREVU(i) Skin Cholesterol Test Assets 67
Kardia Health Systems Partners with TomTec Imaging Systems 67
TriLink and Biofortuna Ink Licensing Agreement 67
Corgenix Enters into a Strategic Alliance with ELITech 68
VaxGen to Merge with diaDexus 68
St. Jude Medical to Take Over LightLab Imaging 68
GE Healthcare and CardioDx Enter into Strategic Alliance 69
bioMerieux and Knome Ink Strategic Partnership Agreement 69
Merge Healthcare Acquires AMICAS 69
Diamedix and Nova Ink Distribution Agreement 70
Inverness Acquires Standard Diagnostics 70
Quidel Acquires Diagnostic Hybrids 70
bioMerieux Acquires Meikang Biotech 70
Aurora Health Care Partners with Celera 71
Mediscience Technology Corporation Acquires SensiVida Medical
Systems 71
Volcano Acquires Axsun Technologies 71
Thermo Fisher Takes Over B.R.A.H.M.S. 71
SonoSite Acquires CardioDynamics International 72
IntriCon Snaps Up Datrix 72
ST. Jude Medical Receives US FDA and European Approval for
EnSite Velocity™ Cardiac Mapping System 72
Roche Inks Agreement with Response Biomedical 72
Dynatek Dalta Scientific Inks Agreement with State Food and
Drug Administration 73
Amic Inks Licensing Deal with Roche Diagnostics 73
TRICARE Includes Atherotech's VAP® Test 73
PreMD Receives NSE Letter from US FDA for POC Skin Cholesterol
Test 74
Amic Gains License for Roche's Cardiac Marker 74
diaDexus and Fisher HealthCare Sign Agreement 74
Inverness Inks Distribution Agreement with PrognostiX 75
GE Healthcare Enters into Collaboration with Boston Scientific 75
St. Jude Medical Acquires EP MedSystems 75
11. INDUSTRY ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER 76
Inverness Takes Over Biosite 76
Siemens Medical Acquires Dade Behring 76
Inverness Medical Innovations Acquires Cholestech 76
Acrongenomics, Pearson and Molecular Enter into Joint Venture 77
Cholestech Teams Up with Onsite Health Diagnostics 77
Lipomics to Collaborate with Agilent Technologies to Develop
Diagnostic Tests. 77
Transgenomic and Fiuotecnica Renew Collaboration Agreement 78
Alteon and BioRap Technologies Enter into an Agreement 78
IM Medical Acquires New Technology for Detecting
Cardiovascular Diseases 78
Medtronic Establishes New Business Entity 78
Siemens Medical Acquires Bayer Healthcare's Diagnostics Unit 79
Inverness Medical Innovations Completes Acquisition of HemoSense 79
Spacelabs Acquires Ferraris' Cardiac Unit 79
Global Immune Takes over Primedical International 80
Siemens Acquires Diagnostics Products 80
Cholestech and Life Line Enter into Collaboration 80
LipoScience Signs an Agreement with ARUP 80
Philips Acquires Witt Biomedical 80
CardioDynamics Enters into an OEM Agreement with Shenzhen Mindray 81
Biosense Enters into Strategic Partnership with Siemens
Medical Solutions 81
Dade Behring Approved the Use of FSAP Antibodies by American
Diagnostica 81
Abbott Receives Non-exclusive Sublicense for Diagnostic Use of
PIGF 81
Nanogen Acquires Spectral's Cardiac Test Division 82
Varian Enters into Alliance with LipoScience to Jointly
Develop NMR System 82
Cardiac Services Professionals Establish eCardio Diagnostics 82
Response Biomedical Wins Nonexclusive License Rights for NT-
proBNP and Troponin T 83
Biomerieux gains Nonexclusive License for NT-proBNP 83
Philips and PMI Ink an Agreement for Outpatient Facility 83
LipoScience Enters into an Agreement with LabCorp 83
Abbott and Cleveland Clinic to Co-develop Myeloperoxidase
Cardiac Test 83
Abbott Receives 510(k) Clearance from FDA for Myoglobin Test 84
FDA Clears Additional Claim for Biosite's Triage (R) BNP Test 84
Biosite Inks an Agreement with University of Mainz 84
Dade Behring Receives FDA Clearance for Advanced D-Dimer Assay 84
Nanogen Acquires SYN•X Pharma 84
GE Takes Over Amersham Plc 85
St. Jude Medical Acquires Irvine Biomedical and Epicor 85
SonoSite Snaps Up SonoMetric 85
CardioDynamics Acquires Vermed 85
Philips and EP MedSystems Announce an Alliance Involving
Electrophysiology Solutions 85
Toshiba and ViTAL Enters into an Alliance with Johns Hopkins
University School of Medicine 85
Response Biomedical Collaborates with Shionogi 86
Terumo Signs Agreement with Spencer Technologies 86
Spectral Diagnostics Announces Agreement with NGC Medical 86
Philips Signs Agreement with Fletcher Allen Health Care 86
Spectral Diagnostics Enters into an Agreement with Cardinal
Health 86
Siemens Signs Agreement with MediGuide 86
Biosite Enters into Agreement with DMI BioSciences 87
Cambridge Heart Enters into Agreement with Del Mar Reynolds 87
Cholestech Enters into an Agreement with Itamar Medical 87
Siemens Enters into a Contract with HiPGraphics 87
Abbott Announces US Clearance for Axis-Shield's BNP Test for
Use on AxSYM 88
Cholestech Announces FDA 510(k) Approval for hs-CRP Test 88
Dade Behring Bags FDA Clearance NT-proBNP Test 88
Dade Behring Receives FDA Clearance for N High Sensitivity CRP
Assay 88
EP-4 Computerized Cardiac Stimulator Bags FDA Approval 88
Biosite Adds two new offices 88
Bayer Diagnostics Enhances BNP Assay Offering Globally 89
EP MedSystems Garners CE Approval for ALERT Deflectable CS
Catheter in Europe 89
Cambridge Heart Inc. and Quinton Cardiology Systems Renew Pact 89
EPIX and Schering AG Extends Collaboration Agreement 90
Siemens Ultrasound and TomTec Imaging Systems Announces Agreement 90
FIT Biotech Plc Acquires Xenerate Ab to Develop Innovative
Cardiovascular Devices 90
Beckman Coulter Enters into Agreement with Biosite 90
Dade Behring Garners Non-exclusive Rights for a Key Cardiac
Marker 91
Bracco Diagnostics Inc., Joins Hand with Eastern Isotopes Inc
to Develop CardioGen-82® 91
New Lab Test from diaDexus Receives FDA Clearance 91
Hypertension Diagnostics Receives SDA Approval in China 91
12. FOCUS ON SELECT GLOBAL PLAYERS 92
AccuTech, LLC (USA) 92
Abbott Diagnostics (USA) 92
Alere Inc. (USA) 92
Biosite, Inc. (USA) 94
Ani Biotech Oy (Finland) 94
Axis-Shield PoC (UK) 94
Beckman Coulter, Inc. (USA) 95
biomerieux (France) 95
Cambridge Heart, Inc. (USA) 95
Cholestech Corp. (USA) 96
GE HealthCare (UK) 96
Home Access Health Corporation (USA) 97
LifeSign LLC (USA) 97
Liposcience, Inc. (USA) 97
Nanosphere, Inc. (USA) 98
Ortho-Clinical Diagnostics, Inc. (USA) 98
Philips Healthcare (USA) 98
Polymer Technology Systems, Inc. (USA) 99
Response Biomedical Corp. (Canada) 99
Roche Diagnostics (Switzerland) 100
Siemens Healthcare Diagnostics, Inc. (USA) 100
St. Jude Medical, Inc. (USA) 101
EP MedSystems (USA) 101
13. GLOBAL MARKET PERSPECTIVE 102
Table 11: World Recent Past, Current & Future Market Analysis
for Cardiovascular Disease Diagnostics by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 102
Table 12: World Historic Review for Cardiovascular Disease
Diagnostics by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Middle East, and Latin America
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 103
Table 13: World 11-Year Perspective for Cardiovascular Disease
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets for
Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 104
Table 14: World Recent Past, Current & Future Market Analysis
for Cardiovascular In Vitro Diagnostics by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 105
Table 15: World Historic Review for Cardiovascular In Vitro
Diagnostics by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Middle East and Latin America
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 106
Table 16: World 11-Year Perspective for Cardiovascular In
Vitro Diagnostics by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets for
Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 107
Table 17: World Recent Past, Current & Future Market Analysis
for Cardiovascular In Vivo Diagnostics by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 108
Table 18: World Historic Review for Cardiovascular In Vivo
Diagnostics by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Middle East and Latin America
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 109
Table 19: World 11-Year Perspective for Cardiovascular In Vivo
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets for
Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 110
14. THE UNITED STATES 111
A.Market Analysis 111
Trends and Issues 111
Innovations Drive the Usage of Cardiovascular Monitoring
Systems 111
Cholesterol POCT Market: An Overview 111
Table 20: US Cholesterol Point-of-Care Testing (2009):
Market Shares of Leading Players by Value Sales for
Inverness Medical, Polymer Technology Systems, and Roche
Diagnostics (includes corresponding Graph/Chart) 112
Increasing Cardiovascular Ailments Drive Sales of Home Test
Devices 112
CHF Biomarkers to Spearhead the US market 112
Table 21: US AMI (Acute Myocardial Infarction) Diagnostics
Market: Market Share by Revenue held by Major Players
(Dade Behring, Beckman Coulter, Bayer Diagnostics, and
Others) in 2006 (includes corresponding Graph/Chart) 113
Table 22: US CHF (Congestive Heart Failure) Diagnostics
Market: Market Share by Revenue held by Major Players
(Dade Behring, Beckman Coulter, Bayer Diagnostics, and
Others) in 2006 (includes corresponding Graph/Chart) 113
Cardiovascular Disease Prevalence in the US 113
Key Statistics on Cardiovascular Diseases 114
Mortality Statistics 114
Table 23: Prevalence of Cardiovascular Disease in the US
(2004): A Historic Review (includes corresponding
Graph/Chart) 115
Table 24: Percentage Breakdown of Deaths from
Cardiovascular Diseases in the US (2004): A Historic Review
(includes corresponding Graph/Chart) 115
Table 25: Prevalence of Cardiovascular Diseases among
Americans by Age (Age 20 and Older) and Sex (2004): A
Historic Review (includes corresponding Graph/Chart) 116
Table 26: A Factoid of CHD and MI (In Million) in the US
(2003): A Historic Review 116
Startling facts related to Stroke in US 116
Table 27: A Factoid of Stroke (In Million) in the US
(2003): A Historic Review 117
Incidence of Coronary Heart Disease 117
AHA Statistics for Coronary Heart Disease 117
Mortality rates of CHD 118
Table 28: Annual Number of Americans Having Diagnosed
Heart Attack by Age and Sex (2004) (includes corresponding
Graph/Chart) 118
Table 29: Prevalence of CHD by Age and Sex (2004) (In %
population) (includes corresponding Graph/Chart) 119
Arrhythmias 119
CAD Diagnostics 119
PVD Diagnostics 120
Medicare Reimbursement Set for CPT Code 83704 120
Competitive Glance 120
Point-of-Care (POC) Diagnostics Market in the US 120
Table 30: Leading Players in the US POC Cardiac Market
(2004) - Percentage Breakdown by Value Sales for Biosite,
Dade Behring, Spectral Diagnostics, Roche and Others
(includes corresponding Graph/Chart) 121
B.Market Analytics 121
Table 31: US Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 121
Table 32: US Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 122
Table 33: US 11-Year Perspective for Cardiovascular Disease
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for In Vitro Diagnostics and In Vivo
Diagnostics Markets for 2005, 2010 & 2015 122
15. CANADA 123
A.Market Analysis 123
Cardiovascular Disease Facts 123
B.Market Analytics 123
Table 34: Canadian Recent Past, Current & Future Analysis
for Cardiovascular Disease Diagnostics by Product Segment -
In Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 123
Table 35: Canadian Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 124
Table 36: Canadian 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 124
16. JAPAN 125
Market Analysis 125
Table 37: Japanese Recent Past, Current & Future Analysis
for Cardiovascular Disease Diagnostics by Product Segment -
In Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 125
Table 38: Japanese Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 126
Table 39: Japanese 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 126
17. EUROPE 127
A.Market Analysis 127
In Vivo Diagnostics - Major Segment in CVD Diagnostics Market 127
Germany - The Largest European Market 127
Cardiovascular Disease - Mortality Statistics 127
Table 40: Leading Cause of Death Among Men in Europe
(2007): Percentage Breakdown for Cardiovascular Diseases,
Poisoning and Injuries, Respiratory Disease, Cancer, and
Others (includes corresponding Graph/Chart) 128
Table 41: Leading Cause of Death Among Women in Europe
(2007): Percentage Breakdown for Cardiovascular Diseases,
Poisoning and Injuries, Respiratory Disease, Cancer, and
Others (includes corresponding Graph/Chart) 128
Cardiovascular Disease - Risk Factor Profile 128
The Cardiovascular Disease Cost Burden 129
B.Market Analytics 129
Table 42: European Recent Past, Current & Future Analysis
for Cardiovascular Disease Diagnostics by Geographic Region
- France, Germany, Italy, UK, Spain, Russia & Rest of Europe
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 129
Table 43: European Historic Review for Cardiovascular
Disease Diagnostics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia & Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 130
Table 44: European Recent Past, Current & Future Analysis
for Cardiovascular Disease Diagnostics by Product Segment -
In Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 131
Table 45: European Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 132
Table 46: European 11-Year Perspective for Cardiovascular
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Sales for France, Germany, Italy, UK, Spain, Russia &
Rest of Europe Markets for Years 2000, 2007 & 2010 (includes
corresponding Graph/Chart) 133
Table 47: European 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 133
17a. FRANCE 134
Market Analysis 134
Table 48: French Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 134
Table 49: French Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 135
Table 50: French 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 135
17b. GERMANY 136
Market Analysis 136
Table 51: German Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 136
Table 52: German Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 137
Table 53: German 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 137
17c. ITALY 138
Market Analysis 138
Table 54: Italian Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 138
Table 55: Italian Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 139
Table 56: Italian 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 139
17d.THE UNITED KINGDOM 140
A.Market Analysis 140
UK Cardiovascular Diseases Fact Sheet 140
B.Market Analytics 141
Table 57: UK Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 141
Table 58: UK Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 142
Table 59: UK 11-Year Perspective for Cardiovascular Disease
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for In Vitro Diagnostics and In Vivo
Diagnostics Markets for 2005, 2010 & 2015 142
17e. SPAIN 143
Market Analysis 143
Table 60: Spanish Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 143
Table 61: Spanish Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 144
Table 62: Spanish 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 144
17f.RUSSIA 145
A.Market Analysis 145
Major Players 145
B.Market Analytics 146
Table 63: Russian Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 146
Table 64: Russian Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 147
Table 65: Russian 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 147
17g. REST OF EUROPE 148
Market Analysis 148
Table 66: Rest of Europe Market for Cardiovascular Disease
Diagnostics - Recent Past, Current & Future Market Analysis
by Product Segment for In Vitro Diagnostics and In Vivo
Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 148
Table 67: Rest of Europe Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 149
Table 68: Rest of Europe 11-Year Perspective for
Cardiovascular Disease Diagnostics by Product Segment -
Percentage Breakdown of Dollar Sales for In Vitro
Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 &
2015 149
18. ASIA PACIFIC 150
A.Market Analysis 150
Cardiovascular Market in Asia-Pacific 150
China 150
Healthcare Expenditure to Grow Considerably by 2015 150
In vitro Diagnostics Market Poised for Strong Growth 151
Domestic Manufacturers Pose a Threat for Overseas IVD
Manufacturers 151
Leading Players 151
Cardiovascular Disease Patients Overview 151
Treatment Providers and Hospitals Overview 152
Hospitals 152
Table 69: Cardiovascular Special Treatment Hospitals in
China: 1991-2011(In numbers) (includes corresponding
Graph/Chart) 152
Chinese Cardiovascular Disease Treatment as a Part of
Overall Health Care Industry 152
Table 70: Cardiovascular Disease Treatment in China:
1991-2006 (includes corresponding Graph/Chart) 153
B.Market Analytics 153
Table 71: Asia-Pacific Market for Cardiovascular Disease
Diagnostics - Recent Past, Current & Future Market Analysis
by Product Segment for In Vitro Diagnostics and In Vivo
Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 153
Table 72: Asia-Pacific Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 154
Table 73: Asia-Pacific 11-Year Perspective for
Cardiovascular Disease Diagnostics by Product Segment -
Percentage Breakdown of Dollar Sales for In Vitro
Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 &
2015 154
19. THE MIDDLE EAST 155
Market Analysis 155
Table 74: The Middle East Market for Cardiovascular Disease
Diagnostics - Recent Past, Current & Future Market Analysis
by Product Segment for In Vitro Diagnostics and In Vivo
Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) 155
Table 75: The Middle East Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 156
Table 76: The Middle East 11-Year Perspective for
Cardiovascular Disease Diagnostics by Product Segment -
Percentage Breakdown of Dollar Sales for In Vitro
Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 &
2015 156
20. LATIN AMERICA 157
A.Market Analysis 157
Brazil: A Growing Market for IVD 157
Table 77: Brazilian IVD Market by Segment (2009):
Percentage Share Breakdown for Immunoassay, Hormone,
Microbiology, Biochemistry, Hematology, Molecular
Diagnostics, Cardiac markers, Hemostasis, and Cytology
(includes corresponding Graph/Chart) 157
B.Market Analytics 158
Table 78: Latin American Market for Cardiovascular Disease
Diagnostics - Recent Past, Current & Future Market Analysis
by Product Segment for In Vitro Diagnostics and In Vivo
Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 158
Table 79: Latin American Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 159
Table 80: Latin American 11-Year Perspective for
Cardiovascular Disease Diagnostics by Product Segment -
Percentage Breakdown of Dollar Sales for In Vitro
Diagnostics and In Vivo Diagnostics Markets for 2000, 2010 &
2015 159
COMPETITIVE LANDSCAPE
Total Companies Profiled: 71 (including Divisions/Subsidiaries - 82)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 57
Canada 3
Japan 4
Europe 15
France 1
Germany 1
The United Kingdom 5
Italy 3
Rest of Europe 5
Asia-Pacific (Excluding Japan) 1
Middle-East 2
------------------------------------------
To order this report:
: Global Cardiovascular Disease Diagnostics Industry
Check our Company Profile, SWOT and Revenue Analysis!
SOURCE Reportlinker
Share this article